Question 1

What is the catalog number for Tissue FFPE Sections, Hip?

Accepted Answer

The catalog number for Tissue FFPE Sections, Hip is CS706931.

Question 2

What sizes are available for Tissue FFPE Sections, Hip?

Accepted Answer

Tissue FFPE Sections, Hip is available in the following size(s): 5x 5 µm.

Question 3

Is Tissue FFPE Sections, Hip in stock?

Accepted Answer

Tissue FFPE Sections, Hip is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Where can I find the safety data sheet (SDS/MSDS) for Tissue FFPE Sections, Hip?

Accepted Answer

The safety data sheet for Tissue FFPE Sections, Hip is available here: https://cdn.origene.com/sds/cs706931.pdf.

Question 5

What is Tissue FFPE Sections, Hip used for?

Accepted Answer

Tissue Sections (5x5um), FFPE; Hip; Degenerative joint disease

Question 6

Is there an additional fee for hazardous or dry ice shipping of this product?

Accepted Answer

Yes, if this product requires dry ice or is classed as hazardous for transport, the additional fee will be explicitly shown in your quotation before you confirm the order, so there are no surprise charges later.

Question 7

How many freeze-thaw cycles can this product tolerate?

Accepted Answer

We recommend aliquoting the product upon receipt to avoid repeated freeze-thaw cycles, which can reduce activity and stability. This is your responsibility once the product has been delivered.

Question 8

Is antigen retrieval required for IHC with this antibody?

Accepted Answer

Recommended antigen retrieval methods, where applicable, are listed on the datasheet under the IHC protocol section.

Tissue FFPE Sections, Hip

Product Specifications

Stability

Storage Conditions

Frequently Asked Questions

Explore Other Products

Cd3e Hamster Monoclonal Antibody [Clone ID: 145-2C11]

Blonanserin

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (N/A), 0.2mg/mL

PNRC2 Human Gene Knockout Kit (CRISPR)

Purified Anti-Human CD36 Antibody[5-271]

Purified Anti-Human CD36 Antibody[5-271]